Conventional MRI evaluation of gliomas
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
MRI using T(1) weighted, T(2) weighted and gadolinium-enhanced sequences plays a central clinical role in diagnosis, characterisation, surveillance and therapeutic monitoring of gliomas. Such conventional MRI protocols provide high resolution multiplanar structural information, and substantially improved tissue characterisation compared with CT. However, the MRI signal lacks biological specificity, e.g. T(2) weighted dependent signal abnormality is dominated by tissue water content, and contrast enhancement reflects a non-specific increase in blood-brain barrier permeability. This limits non-invasive glioma diagnosis, characterisation and therapeutic planning and assessment of active tumour load may be confounded by treatment-related effects. The complex features of glioma morphology and often subtle changes between MRI examinations are also frequently difficult to detect reliably by visual inspection of the images, even by an experienced radiologist. Moreover, the most widely used response criteria in clinical practice and therapeutic trials rely on linear measurements of enhancing tumour and are further challenged by the irregular shape and heterogeneous composition of gliomas. This contributes to the poor correlation of these criteria with hard clinical endpoints. While conventional MRI is widely available and provides essential anatomical information, the lack of pathology-specific biomarkers available from standard MRI sequences and methods of image analysis used limit overall diagnostic and prognostic efficacy of the examination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 2×
“A small number of studies have attempted to validate this unidimensional approach [12, 13] and found comparable results when using the MacDonald criteria and RECIST criteria.”
BackgroundResultWen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., DeGroot, J., Wick, W., Gilbert, M. R., Lassman, A. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3541 · Cited by 3,836 · cited 2×
“This issue has also been acknowledged by the RANO group, who suggest that within 12 weeks of chemoradiotherapy, progression can only be defined on imaging if there is new enhancement outside the radiation field [15].”
BackgroundResponse criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409 · cited 1×
“Macdonald et al [10] adapted these for brain tumours in 1990, suggesting steroid treatment and clinical deterioration should also be considered when establishing response.”
MethodClinical features, mechanisms, and management of pseudoprogression in malignant gliomas
Brandsma, D., Stalpers, L., Taal, W., Sminia, P., & van den Bent, M. J. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70125-6 · Cited by 1,121 · cited 1×
“Radiological pseudoprogression, where transient increases in apparent tumour size and enhancement are seen during and shortly after aggressive chemoradiotherapy regimens, is also increasingly recognised [21].”
BackgroundMR imaging correlates of survival in patients with high-grade gliomas.
Pope, W. B., Sayre, J. W., Perlina, A., Villablanca, J. P., Mischel, P. S., & Cloughesy, T. F. (2005) · PubMed Central · Cited by 418
How often are nonenhancing supratentorial gliomas malignant? A population study
Scott, J. N., Brasher, P. M. A., Sevick, R. J., Rewcastle, N. B., & Forsyth, P. A. (2002) · Neurology · doi:10.1212/wnl.59.6.947 · Cited by 366 · cited 2×
“Certain subtypes of LGGs, notably gangliogliomas and pilocytic astrocytomas, some grade II oligodendrogliomas [3] and more rarely, low-grade astrocytomas [2], show enhancement.”
BackgroundImmediate post-radiotherapy changes in malignant glioma can mimic tumor progression
de Wit, M. C. Y., de Bruin, H. G., Eijkenboom, W., Sillevis Smitt, P. A. E., & van den Bent, M. J. (2004) · Neurology · doi:10.1212/01.wnl.0000133398.11870.9a · Cited by 357 · cited 1×
“It has long been known that radionecrosis may manifest as oedema and enhancement, which can be impossible to distinguish from progressive tumour using conventional MRI [18–20], and a range of non-specific enhancement patterns have been demonstrated [19].”
BackgroundImmediate post-radiotherapy changes in malignant glioma can mimic tumor progression
Box, P. (2005) · Dkgest of the World Latest Medical Information · Cited by 299
Advanced MR Imaging Techniques in the Diagnosis of Intraaxial Brain Tumors in Adults
Al-Okaili, R. N., Krejza, J., Wang, S., Woo, J. H., & Melhem, E. R. (2006) · RadioGraphics · doi:10.1148/rg.26si065513 · Cited by 276 · cited 1×
“Although some intracranial masses have sufficiently distinctive radiological features to allow confident imaging diagnosis, conventional structural imaging has limited specificity in distinguishing brain tumours from other non-neoplastic diseases that can present as spaceoccupying lesions [1].”
BackgroundMRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy
Pope, W. B., Lai, A., Nghiemphu, P., Mischel, P., & Cloughesy, T. F. (2006) · Neurology · doi:10.1212/01.wnl.0000208958.29600.87 · Cited by 271 · cited 1×
“patients treated with bevacizumab showed response in areas of necrotic tumour, while areas of solid tumour continued to grow [17].”
BackgroundMRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy
Chamberlain, M. C. (2006) · Neurology · doi:10.1212/01.wnl.0000250628.10420.d8 · Cited by 264
Shah, G. D., Kesari, S., Xu, R., Batchelor, T. T., O'Neill, A. M., Hochberg, F. H., Levy, B., Bradshaw, J., & Wen, P. Y. (2006) · Neuro-Oncology · doi:10.1215/s1522851705000529 · Cited by 195 · cited 2×
“However, one study has shown evidence of correlation between linear methods and overall survival at 2 months that could not be reproduced at 6 months [13].”
BackgroundResultSorensen, A. G., Batchelor, T. T., Wen, P. Y., Zhang, W.-T., & Jain, R. K. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1204 · Cited by 192 · cited 3×
“Although the Macdonald criteria have been widely adopted, they have been criticised for being ambiguous in defining the appropriate threshold for lesion size and lacking detail in how to apply the criteria [11].”
BackgroundMethodInfluentialØstergaard, L., Hochberg, F. H., Rabinov, J. D., Sorensen, A. G., Lev, M., Kim, L., Weisskoff, R. M., Gonzalez, R. G., Gyldensted, C., & Rosen, B. R. (1999) · Journal of Neurosurgery · doi:10.3171/jns.1999.90.2.0300 · Cited by 171 · cited 1×
“Steroid treatment has been shown to decrease blood– tumour barrier permeability and regional cerebral blood volume [22].”
BackgroundPope, W. B., Chen, J. H., Dong, J., Carlson, M. R. J., Perlina, A., Cloughesy, T. F., Liau, L. M., Mischel, P. S., Nghiemphu, P., Lai, A., et al. (2008) · Radiology · doi:10.1148/radiol.2491072000 · Cited by 149
Measurement of tumor "size" in recurrent malignant glioma: 1D, 2D, or 3D?
Dempsey, M. F., Condon, B. R., & Hadley, D. M. (2005) · PubMed · Cited by 147
Galanis, E., Buckner, J. C., Maurer, M. J., Sykora, R., Castillo, R., Ballman, K. V., & Erickson, B. J. (2006) · Neuro-Oncology · doi:10.1215/15228517-2005-005 · Cited by 139
White, M. L., Zhang, Y., Kirby, P., & Ryken, T. C. (2005) · PubMed · Cited by 119
Carlson, M. R. J., Pope, W. B., Horvath, S., Braunstein, J. G., Nghiemphu, P., Tso, C.-L., Mellinghoff, I., Lai, A., Liau, L. M., Mischel, P. S., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2772 · Cited by 118 · cited 1×
“Oedema is the most commonly cited negative predictor [8, 24].”
BackgroundAghi, M. K., Gaviani, P., Henson, J. W., Batchelor, T. T., Louis, D. N., & Barker, F. G. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0713 · Cited by 109 · cited 5×
“Primary or de novo glioblastomas are associated with epidermal growth factor receptor amplification, and are associated with larger enhancing components relative to overall tumour volume and ill-defined margins compared with secondary glioblastoma arising from LGG [6, 7].”
BackgroundInfluentialAssessment of the pathological grade of astrocytic gliomas using an MRI score
Asari, S., Makabe, T., Katayama, S., Itoh, T., Tsuchida, S., & Ohmoto, T. (1994) · Neuroradiology · doi:10.1007/bf00593267 · Cited by 75
Cited by
Patel, S. H., Poisson, L. M., Brat, D. J., Zhou, Y., Cooper, L., Snuderl, M., Thomas, C., Franceschi, A. M., Griffith, B., Flanders, A. E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0560 · Cited by 424
Machine Learning–Based Radiomics for Molecular Subtyping of Gliomas
Lu, C.-F., Hsu, F.-T., Hsieh, K. L.-C., Kao, Y.-C. J., Cheng, S.-J., Hsu, J. B.-K., Tsai, P.-H., Chen, R.-J., Huang, C.-C., Yen, Y., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3445 · Cited by 306
Feng, X., Tustison, N. J., Patel, S. H., & Meyer, C. H. (2020) · Frontiers in Computational Neuroscience · doi:10.3389/fncom.2020.00025 · Cited by 267
Figueroa, J. M., Skog, J., Akers, J., Li, H., Komotar, R., Jensen, R., Ringel, F., Yang, I., Kalkanis, S., Thompson, R., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox085 · Cited by 204
Amin, J., Sharif, M., Yasmin, M., Saba, T., Anjum, M. A., & Fernandes, S. L. (2019) · Journal of Medical Systems · doi:10.1007/s10916-019-1453-8 · Cited by 147
Metadata
- Authors
- Upadhyay, N., & Waldman, A. D.
- Venue
- The British Journal of Radiology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-12
- Volume
- 84
- Issue
- special_issue_2
- Pages
- S107-S111
- ISSN
- 0007-1285 (ISSN-L)
- 1748-880X
- OpenAlex
- W2056342586
- Cited by
- 243
- References
- 21
- FWCI
- 1.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.